Tandem Diabetes Care Receives Consensus Rating of “Buy” from Analysts (NASDAQ:TNDM)
Tandem Diabetes Care (NASDAQ:TNDM) has received an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Analyst Ratings Net reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $20.75.
Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded down 2.41% during mid-day trading on Friday, hitting $14.0139. The stock had a trading volume of 15,195 shares. Tandem Diabetes Care has a 1-year low of $1.791 and a 1-year high of $30.25. The stock has a 50-day moving average of $13.86 and a 200-day moving average of $17.73. The company’s market cap is $328.8 million.
Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.08. The company had revenue of $10.26 million for the quarter, compared to the consensus estimate of $10.36 million. The company’s quarterly revenue was up 85.5% on a year-over-year basis.
In other Tandem Diabetes Care news, COO John F. Sheridan unloaded 2,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $13.99, for a total value of $27,980.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
TNDM has been the subject of a number of recent research reports. Analysts at Feltl & Co. initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday. They set a “strong-buy” rating on the stock. Separately, analysts at Bank of America upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating in a research note on Friday, August 1st. Finally, analysts at Deutsche Bank reiterated a “buy” rating on shares of Tandem Diabetes Care in a research note on Friday, August 1st. They now have a $25.00 price target on the stock.
Tandem Diabetes Care, Inc is a medical device company with an approach to design, develop and commercialize products for people with insulin-dependent diabetes.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.